Athersys begins clinical trial for MultiStem cell therapy for COVID-19

By The Science Advisory Board staff writers

May 5, 2020 -- Athersys announced that it has begun enrollment in its phase II/III study named MultiStem Administration for COVID-19 Induced Acute Respiratory Distress Syndrome (MACOVIA).

Patients were enrolled at University Hospitals Cleveland Medical Center. The program will evaluate the administration of MultiStem for the treatment of acute respiratory distress syndrome (ARDS); the therapy was recently granted fast track designation by the U.S. Food and Drug Administration (FDA) based on promising phase I/II data from its MUST-ARDS trial. As there are currently no FDA-approved medicines for the treatment of ARDS, this therapy could provide an unmet need for COVID-19 patients.

The study will enroll approximately 400 subjects who will receive open-label, single-active treatment to evaluate the safety of MultiStem administered at two dose levels to patients with moderate to severe ARDS associated with COVID-19. If MultiStem is deemed efficacious, safe, and tolerable, the company will further evaluate the treatment with a double-blind, randomized, and placebo-controlled trial protocol.

The company is working with Medpace, a contract research organization, for the study. The firm is also in discussions with the Biomedical Advanced Research and Development Authority (BARDA) to expedite the development of its therapy.

Copyright © 2020

BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Cell & Gene Meeting on the Mesa
October 11-13
Carlsbad, California United States
IDWeek 2022
October 19-23
District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter